DK1680128T3 - Myo-inositolhexaphosphat til topisk anvendelse - Google Patents

Myo-inositolhexaphosphat til topisk anvendelse

Info

Publication number
DK1680128T3
DK1680128T3 DK04798764T DK04798764T DK1680128T3 DK 1680128 T3 DK1680128 T3 DK 1680128T3 DK 04798764 T DK04798764 T DK 04798764T DK 04798764 T DK04798764 T DK 04798764T DK 1680128 T3 DK1680128 T3 DK 1680128T3
Authority
DK
Denmark
Prior art keywords
myo
inositol hexaphosphate
topical use
development
treatment
Prior art date
Application number
DK04798764T
Other languages
Danish (da)
English (en)
Inventor
Freixedas F Grases
Bestard J Perello
Amengual B Isern
Almirall R Prieto
Bauza A Costa
Original Assignee
Sanifit S L Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanifit S L Lab filed Critical Sanifit S L Lab
Application granted granted Critical
Publication of DK1680128T3 publication Critical patent/DK1680128T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK04798764T 2003-11-07 2004-11-03 Myo-inositolhexaphosphat til topisk anvendelse DK1680128T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200302600A ES2232302B1 (es) 2003-11-07 2003-11-07 Myo-inositol hexafosfato para uso topico.
PCT/IB2004/003588 WO2005044278A1 (fr) 2003-11-07 2004-11-03 Hexaphosphate de myo-inositol pour usage topique

Publications (1)

Publication Number Publication Date
DK1680128T3 true DK1680128T3 (da) 2007-06-11

Family

ID=34566008

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04798764T DK1680128T3 (da) 2003-11-07 2004-11-03 Myo-inositolhexaphosphat til topisk anvendelse

Country Status (15)

Country Link
US (1) US20070066574A1 (fr)
EP (1) EP1680128B1 (fr)
JP (1) JP4786543B2 (fr)
AT (1) ATE353655T1 (fr)
BR (1) BRPI0415713A (fr)
CA (1) CA2544963C (fr)
CY (1) CY1106574T1 (fr)
DE (1) DE602004004817T2 (fr)
DK (1) DK1680128T3 (fr)
ES (2) ES2232302B1 (fr)
MX (1) MXPA06005043A (fr)
PL (1) PL1680128T3 (fr)
PT (1) PT1680128E (fr)
SI (1) SI1680128T1 (fr)
WO (1) WO2005044278A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
CA2488230C (fr) * 2002-04-29 2013-04-09 Yves Claude Nicolau Inositol pyrophosphates et procede d'utilisation desdits composes
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
WO2006102060A1 (fr) * 2005-03-18 2006-09-28 Oxyplus, Inc. Sel de calcium de myo-inositol 1,6:2,3:4,5 tripyrophosphate utile comme effecteur allosterique de l'hemoglobine
ES2272191B1 (es) * 2005-10-14 2008-04-01 Universitat De Les Illes Balears Utilizacion del fitato para el tratamiento del agua.
ES2280136B1 (es) * 2006-02-17 2008-08-16 Universitat De Les Illes Balears Asociacion a dosis fija de fitato y zinc.
ES2288126B2 (es) * 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
CN101784193A (zh) * 2007-05-01 2010-07-21 诺尔姆奥克西斯公司 促红细胞生成素互补或替代
ES2332636B1 (es) * 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
ES2495666B1 (es) * 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
DE102016013737A1 (de) 2016-11-17 2018-05-17 WindplusSonne GmbH Hexahydroxycyclohexanhexaphosphorsäureestersalze zur Behandlung von Kalzinose sowie diätische Lebensmittel mit Hexahydroxycyclohexanhexaphosphorsäureestersalzen als Zusatzstoffe
WO2019176693A1 (fr) * 2018-03-15 2019-09-19 国立大学法人広島大学 Inhibiteur de l'expression du facteur lié à la formation osseuse ou au facteur lié à la calcification dans un tissu extrasquelettique
MX2021003653A (es) * 2018-10-11 2021-06-23 Sanifit Therapeutics S A Inositol fosfatos para el tratamiento de calcificacion ectopica.
JP2022521119A (ja) 2019-01-30 2022-04-06 サニフィット・セラピューティクス・ソシエダッド・アノニマ 組織の灌流の増加における使用のためのイノシトールリン酸化合物
EP3818983A1 (fr) 2019-11-11 2021-05-12 Sanifit Therapeutics S.A. Composés de phosphate d'inositol pour une utilisation dans le traitement, l'inhibition de la progression ou la prévention de la calcification cardiovasculaire
EP4015494A1 (fr) 2020-12-15 2022-06-22 Sanifit Therapeutics S.A. Procédés de préparation de sels solubles de phosphates d'inositol
EP4036097A1 (fr) 2021-01-29 2022-08-03 Sanifit Therapeutics S.A. Composés dérivés substitués de l'ip4-4,6
TW202412815A (zh) 2022-07-29 2024-04-01 西班牙商薩尼菲特治療公司 Ip5經取代化合物
WO2024023359A1 (fr) 2022-07-29 2024-02-01 Sanifit Therapeutics, S.A. Composés dérivés substitués en ip4-4,6 destinés à être utilisés dans le traitement, l'inhibition de la progression et la prévention de la calcification ectopique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934002A (en) * 1972-06-30 1976-01-20 The Procter & Gamble Company Oral compositions for plaque, caries and calculus retardation with reduced staining tendencies
JPH01305033A (ja) * 1988-06-01 1989-12-08 Sanwa Kagaku Kenkyusho Co Ltd 循環改善剤及び循環改善機能性食品並びにし好品
US5082833A (en) * 1988-06-30 1992-01-21 Shamsuddin Abulkalam M Reduction of cell proliferation and enhancement of nk-cell activity
US5268176A (en) * 1991-07-22 1993-12-07 Avon Products, Inc. Method and compositions for the non-invasive treatment of telangiectasia
US5516801A (en) * 1992-08-21 1996-05-14 Scotia Holdings Plc Fatty acid treatment for ectopic calcium deposition
DE4444238A1 (de) * 1994-12-13 1996-06-20 Beiersdorf Ag Kosmetische oder dermatologische Wirkstoffkombinationen aus Zimtsäurederivaten und Flavonglycosiden
US6359194B1 (en) * 1995-02-10 2002-03-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5536499A (en) * 1995-02-24 1996-07-16 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for reducing or preventing signs of cellulite
US5821237A (en) * 1995-06-07 1998-10-13 The Procter & Gamble Company Compositions for visually improving skin
US5614511A (en) * 1996-03-11 1997-03-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions for treating itchy skin
JP3623430B2 (ja) * 2000-07-06 2005-02-23 築野ライスファインケミカルズ株式会社 抗酸化性組成物
JP2003238414A (ja) * 2001-12-13 2003-08-27 Sangaku Renkei Kiko Kyushu:Kk 医薬組成物
EP1327443A1 (fr) * 2001-12-21 2003-07-16 Kyowa Hakko Kogyo Co., Ltd. Agents pour traitement ou prévention des maladies causées par une réduction de l'expression de la protéine klotho

Also Published As

Publication number Publication date
CA2544963C (fr) 2010-03-30
ATE353655T1 (de) 2007-03-15
EP1680128A1 (fr) 2006-07-19
US20070066574A1 (en) 2007-03-22
ES2232302B1 (es) 2006-08-01
JP4786543B2 (ja) 2011-10-05
ES2232302A1 (es) 2005-05-16
PL1680128T3 (pl) 2007-07-31
MXPA06005043A (es) 2007-03-15
DE602004004817D1 (de) 2007-03-29
CA2544963A1 (fr) 2005-05-19
PT1680128E (pt) 2007-05-31
WO2005044278A1 (fr) 2005-05-19
SI1680128T1 (sl) 2007-08-31
EP1680128B1 (fr) 2007-02-14
DE602004004817T2 (de) 2007-11-22
CY1106574T1 (el) 2012-01-25
JP2007510710A (ja) 2007-04-26
BRPI0415713A (pt) 2006-12-19
ES2282920T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
DK1680128T3 (da) Myo-inositolhexaphosphat til topisk anvendelse
MXPA05011208A (es) Uso de ivermectina para el tratamiento de desordenes dermatologicos.
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
CR9949A (es) Inhibidores de proteina activadora de la 5-lipoxigenasa (flap)
ATE355065T1 (de) Therapeutische zusammensetzungen bestehend aus antihypotensiva und antiangiogenika
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
ATE534378T1 (de) Titrierung von tapentadol
WO2009002867A3 (fr) Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
BRPI0509053A (pt) composição farmacêutica anidra e uso de um agente siliconado e de uma composição
DE602006009259D1 (de) Pharmazeutische zusammensetzung mit einem organopoirkstoff
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
ECSP077843A (es) Tratamiento o prevención del prurito
EA200970353A1 (ru) Комбинированное лекарственное средство
BRPI0611526A2 (pt) composição tópica contendo gelatina
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau
BRPI0512316A (pt) métodos para prevenir ou atenuar uma ou mais complicações da hemorragia intracerebral e para prevenir ou atenuar uma ou mais complicações da ich em uma maioria de pacientes com ich, e, uso de um primeiro agente de coagulação
PT1220676E (pt) Prevencao do cancro colorrectal
EA200801890A1 (ru) Средство для лечения шума в ушах
DK1675611T3 (da) Terapeutiske anvendelser for C-peptid
CR8584A (es) Piperazinas derivadas de urea para el tratamiento de la endometrosis
ATE484288T1 (de) Pharmazeutische zusammensetzungen zur linderung von übermässig hohen zuckerspiegeln bei diabetikern
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
BRPI0510503A (pt) compostos e composições como inibidores de catepsina s